scanance.
Sign inGet Premium
PO

Insulet Corporation

PODDHealthcareNASDAQ

Medical Devices

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$2.71B
+30.7% YoY
Net Income
$247.1M
-40.9% YoY
EBITDA
$489.3M
+15.5% YoY
Free Cash Flow
$253.4M

Scan Results

Daily timeframe
DateIndicatorDetails
Loading...
About Insulet Corporation

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. At a $10.26B market cap, Insulet Corporation ranks as a large-cap company within healthcare. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System.

Key stats
Market Cap$10.26B
P/E (TTM)34.61
Fwd P/E18.31
EPS$4.28
Beta1.20
52W Change-54.2%
ROE23.0%
Analysis

On the balance sheet, PODD has $480.4M in cash with $1.01B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow comes in at $253.4M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at 23.0%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 9.7% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $1.31B (2022) to $2.71B (2025), reflecting a 107% increase over the period.

Investors considering Insulet Corporation should weigh the typical risks associated with PODD's sector, size, and financial profile against their own risk tolerance and investment objectives. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Insulet Corporation and its sector.

Links
Not financial advice. Scanance is an educational tool. Past performance does not guarantee future results.PrivacyTerms